Stratistics MRC에 따르면 세계의 색전 입자 시장은 2025년에 17억 달러를 차지하고 예측 기간 동안 CAGR 12.7%를 나타내 2032년에는 38억 달러에 이를 전망입니다.
색전 입자는 혈관을 의도적으로 막기 위한 색전술로 불리는 의료 치료에 사용되는 작은 합성 또는 천연 물질입니다. 이러한 입자는 카테터를 통해 표적 혈관에 주입되어 종양, 비정상적인 성장 또는 출혈 부위와 같은 특정 부위의 혈류를 차단합니다.
미국 암 협회(American Cancer Society, Inc.)가 발표한 데이터에 따르면, 2024년 1월에는 미국에서 새롭게 약 41,630례의 간암이 그 해에 진단되었습니다.
만성 질환 증가
암, 심혈관 질환, 자궁 근종 등의 만성 질환의 발생률이 증가하면 색전 입자 시장의 큰 성장을 가속하고 있습니다. 표적을 좁힌 치료로 회복이 빠른 치료법에 대한 환자 수요가 높아짐에 따라 색전 기술의 요구가 확대되고 있습니다.
색전술의 높은 비용
색전술의 치료비가 높으면 색전 입자 시장의 성장을 크게 저해하고 있습니다. 비용 때문에 이러한 첨단 기술을 채택하는 데 소극적일 수 있으며 시장 확대를 더욱 방해합니다. 이는 시장 진출자에게 장벽이 되어 기술 혁신을 늦추고 생명을 구할 수 있는 치료의 채용을 제한합니다.
기술 진보
기술의 진보는 정확성, 효능, 환자의 안전성을 높여 색전 입자 시장을 크게 견인하고 있습니다. 이와 같은 획기적인 기술은 투자를 불러들여 종양학, 신경학, 부인과학 등의 임상 응용을 확대하고 있습니다.
엄격한 규제 요건
엄격한 규제 요건은 길고 비용이 많이 드는 승인 프로세스를 부과함으로써 색전 입자 시장의 큰 방해가 되고 있습니다. 엄격한 기준은 개발 비용을 증가시키고, 특히 중소규모의 제조업자에게는 컴플라이언스를 복잡하게 하고 있습니다.
COVID-19의 영향
COVID-19의 대유행은 색전 입자 시장을 크게 혼란시켜, 선택적 처치의 지연이나 입원의 감소를 초래했습니다. 더하여 임상개발 활동에 지장을 주었고, 그 결과 팬데믹의 피크시에는 시장의 성장이 둔화되었습니다.
예측 기간 동안 생분해 부문이 최대가 될 것으로 예상
생분해성 부문은 이러한 입자가 치료 효과를 달성한 후 자연적으로 용해되고 영구 임플란트와 관련된 위험을 최소화하기 때문에 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예측됩니다. 또한 생체적합성에 대한 의식이 높아짐에 따라 수요를 뒷받침하고 있으며, 생분해성 재료의 진보는 치료 정밀도와 치료 후의 회복을 향상시키고, 이 분야를 색전 입자 산업에 있어서의 주요 촉진요인 및 기술 혁신의 촉매로 자리매김하고 있습니다.
신경분야는 예측기간 중 가장 높은 CAGR이 예상됩니다.
예측 기간 동안 동정맥 기형과 같은 신경혈관 장애가 증가함에 따라 신경학 부문이 가장 높은 성장률을 보일 것으로 예측됩니다. 요소에서는 효과적이고 대상을 좁힌 치료를 위해 색전 입자를 채용하는 경우가 늘어나고 있으며, 환자의 결과를 향상시키고 있습니다.
예측 기간 동안 아시아태평양은 고급 인터벤셔널 라디오 로지 기술에 대한 액세스 개선으로 최대 시장 점유율을 차지할 것으로 예측됩니다. 기술의 진보와 의료 관광의 확대도 시장 확대에 기여하고 있습니다.
예측 기간 동안 북미가 가장 높은 CAGR을 나타낼 것으로 예측되지만, 이것은 낮은 침습 절차의 채용이 증가하고 있으며 인터벤셔널 라디올로지의 기술적 진보로 인한 것입니다. 선도 기업들은 R&D에 투자하고 치료의 효율성과 안전성을 높이고 있습니다.
According to Stratistics MRC, the Global Embolization Particle Market is accounted for $1.7 billion in 2025 and is expected to reach $3.8 billion by 2032 growing at a CAGR of 12.7% during the forecast period. Embolization particles are small synthetic or natural materials used in a medical procedure called embolization to block blood vessels deliberately. These particles are injected through a catheter into the targeted blood vessels to obstruct blood flow to specific areas, such as tumors, abnormal growths, or areas of bleeding. By restricting blood supply, embolization can shrink tumors, stop hemorrhaging, or reduce blood loss during surgery. Common materials include polyvinyl alcohol (PVA), microspheres, gelatin sponges, or metal coils. The choice of particle size and material depends on the clinical goal and target vessel size.
According to data published by the American Cancer Society, Inc., in January 2024, about 41,630 new liver cancer cases were estimated to be diagnosed in the U.S. that year.
Rising Incidence of Chronic Diseases
The rising incidence of chronic diseases such as cancer, cardiovascular conditions, and uterine fibroids is driving significant growth in the embolization particle market. These conditions often require minimally invasive procedures for treatment, where embolization particles play a crucial role in blocking abnormal blood flow. As patient demand increases for less invasive, targeted therapies with faster recovery times, the need for embolization technologies expands. This trend fosters innovation, investment, and market expansion, positioning embolization particles as a key therapeutic solution.
High Cost of Embolization Procedures
The high cost of embolization procedures significantly hinders the growth of the embolization particle market. Expensive treatment prices limit patient accessibility, particularly in low-income regions, reducing overall demand. Additionally, healthcare providers may be reluctant to adopt these advanced procedures due to high operational costs, further stalling market expansion. This creates a barrier for market players, slowing innovation and limiting the adoption of potentially life-saving treatments.
Technological Advancements
Technological advancements are significantly driving the embolization particle market by enhancing precision, efficacy, and patient safety. Innovations such as image-guided delivery systems, bioresorbable particles, and nanotechnology enable targeted therapy with minimal invasiveness, reducing recovery time and improving outcomes. These breakthroughs attract investment and expand clinical applications across oncology, neurology, and gynecology. As healthcare shifts toward personalized medicine, technology-driven embolization solutions offer superior customization, boosting adoption and market growth globally.
Stringent Regulatory Requirements
Stringent regulatory requirements significantly hinder the embolization particle market by imposing lengthy and costly approval processes. Regulatory bodies like the FDA and EMA demand extensive clinical trials and comprehensive safety data, delaying market entry for new products. These rigorous standards increase development costs and complicate compliance, particularly for small and mid-sized manufacturers. Such barriers restrict innovation, limit product availability, and impede timely access to advanced treatments, especially in emerging markets.
Covid-19 Impact
The COVID-19 pandemic significantly disrupted the embolization particle market, leading to delays in elective procedures and reduced hospital admissions. Lockdowns and resource reallocation strained supply chains, causing manufacturing and distribution challenges. This resulted in workforce shortages and hindered clinical development activities. Consequently, the market experienced a slowdown in growth during the peak of the pandemic. However, as healthcare systems adapt and elective procedures resume, the market is poised for recovery and continued expansion.
The biodegradable segment is expected to be the largest during the forecast period
The biodegradable segment is expected to account for the largest market share during the forecast period as these particles naturally dissolve after achieving their therapeutic effect, minimizing risks associated with permanent implants. Growing preference for minimally invasive procedures and increasing awareness of biocompatibility are fueling demand. Additionally, advancements in biodegradable materials enhance treatment precision and post-procedural recovery, positioning this segment as a key growth driver and innovation catalyst within the embolization particle industry.
The neurology segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the neurology segment is predicted to witness the highest growth rate, due to rising incidences of neurovascular disorders such as arteriovenous malformations. Advancements in minimally invasive procedures and increased awareness of neurological conditions have spurred demand for precise embolization solutions. Hospitals and clinics are increasingly adopting embolization particles for effective, targeted treatments, enhancing patient outcomes. This strong demand from the neurology field continues to positively impact market expansion, innovation, and investment in embolic technologies globally.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to improved access to advanced interventional radiology procedures. Governments are prioritizing minimally invasive treatments, boosting demand for embolization therapies. Technological advancements and expanding medical tourism further contribute to market expansion. This positive momentum is enhancing patient outcomes, reducing recovery times, and promoting cost-effective healthcare solutions across rapidly developing economies like China, India, and Southeast Asia.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to rising adoption of minimally invasive procedures, and technological advancements in interventional radiology. Growing healthcare expenditure and supportive reimbursement policies further drive market growth. Major players are investing in research and development, enhancing treatment efficacy and safety. This progress fosters better patient outcomes, accelerates procedural demand, and strengthens the region's leadership in global embolization technologies.
Key players in the market
Some of the key players profiled in the Embolization Particle Market include Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Merit Medical Systems, Inc., Cook Medical Inc., Sirtex Medical Limited, BTG plc, Stryker Corporation, Penumbra, Inc., Johnson & Johnson, Guerbet Group, Kaneka Corporation, Interface BIOmaterials B.V., HENGRUI Medical and Alicon.
In February 2025, Medtronic and Philips have partnered to enhance the capabilities of over 300 clinicians in India by providing advanced training in structural heart imaging. This collaboration focuses on equipping cardiologists and radiologists with expertise in multi-modality imaging techniques, particularly echocardiography (echo) and Magnetic Resonance Imaging (MRI), to improve the diagnosis and treatment of structural heart diseases, especially among End-Stage Renal Disease (ESRD) patients.
In July 2024, Medtronic and SWIZTON Medcare have inaugurated their first collaborative vein clinic at Aveksha Hospital in Singapura, Bengaluru. This facility aims to provide accessible and advanced treatments for varicose veins, a condition affecting approximately 20% of adults globally.